XOMA/$XOMA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About XOMA
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.
Ticker
$XOMA
Sector
Primary listing
Employees
13
Headquarters
Website
XOMA Metrics
BasicAdvanced
$396M
-
-$1.37
1.00
-
Price and volume
Market cap
$396M
Beta
1
52-week high
$33.75
52-week low
$18.35
Average daily volume
43K
Financial strength
Current ratio
4.881
Quick ratio
4.854
Long term debt to equity
110.8
Total debt to equity
123.935
Interest coverage (TTM)
-0.64%
Profitability
EBITDA (TTM)
-7.345
Gross margin (TTM)
93.23%
Net profit margin (TTM)
-21.47%
Operating margin (TTM)
-19.49%
Effective tax rate (TTM)
36.95%
Revenue per employee (TTM)
$3,460,000
Management effectiveness
Return on assets (TTM)
-2.35%
Return on equity (TTM)
-10.03%
Valuation
Price to revenue (TTM)
8.662
Price to book
5.46
Price to tangible book (TTM)
14.66
Price to free cash flow (TTM)
-13.451
Free cash flow yield (TTM)
-7.43%
Free cash flow per share (TTM)
-2.435
Growth
Revenue change (TTM)
194.98%
Earnings per share change (TTM)
-36.86%
3-year revenue growth (CAGR)
3.14%
10-year revenue growth (CAGR)
11.85%
3-year earnings per share growth (CAGR)
19.99%
10-year earnings per share growth (CAGR)
-20.80%
What the Analysts think about XOMA
Analyst ratings (Buy, Hold, Sell) for XOMA stock.
Bulls say / Bears say
Strong Q1 2025 profitability and revenue growth: XOMA reported total income and revenues of $15.9 million and net income of $2.4 million in Q1 2025, compared to $1.5 million in revenues and an $8.6 million net loss a year earlier, demonstrating significant operational leverage and milestone achievements (GlobeNewswire).
Strategic late-stage portfolio expansion: In May 2025, XOMA acquired mezagitamab royalty and milestone rights from BioInvent for up to $30 million, increasing its stake in a Phase 3 asset with potential near-term commercial milestones and royalty streams (GlobeNewswire).
Diversified portfolio with multiple catalysts: XOMA’s portfolio spans over 120 assets, including six commercial products (e.g., VABYSMO®, OJEMDA™) and 11 Phase 3 programs, with anticipated 2025 catalysts—such as the EMA decision on tovorafenib and topline data for ersodetug—that could drive additional milestone payments (GlobeNewswire).
Rising research and development expenses: R&D spending climbed to $1.3 million in Q1 2025 from just $33 000 a year earlier, reflecting higher pass-through licensing fees and trial costs that may pressure margins if revenue growth slows (GlobeNewswire).
Declining cash reserves: Cash and cash equivalents decreased to $95.0 million at March 31, 2025 from $106.4 million at December 31, 2024 due to acquisitions and share repurchases, signaling potential liquidity constraints if milestone and royalty receipts decelerate (GlobeNewswire).
Receivables impairment risk: In full-year 2024, XOMA recorded $30.9 million in non-cash credit losses on purchased receivables, highlighting the risk of impairment in its royalty receivables portfolio (GlobeNewswire).
Data summarised monthly by Lightyear AI. Last updated on 1 Aug 2025.
XOMA Financial Performance
Revenues and expenses
XOMA Earnings Performance
Company profitability
XOMA News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for XOMA stock?
XOMA (XOMA) has a market cap of $396M as of August 22, 2025.
What is the P/E ratio for XOMA stock?
The price to earnings (P/E) ratio for XOMA (XOMA) stock is 0 as of August 22, 2025.
Does XOMA stock pay dividends?
No, XOMA (XOMA) stock does not pay dividends to its shareholders as of August 22, 2025.
When is the next XOMA dividend payment date?
XOMA (XOMA) stock does not pay dividends to its shareholders.
What is the beta indicator for XOMA?
XOMA (XOMA) has a beta rating of 1. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.